Follow the entities shaping the evidence.

…tality did not differ (HR 1.039, CI 0.594 to 1.816).Conclusions Metformin could have repurposed benefits in epilepsy. This warrants furth…

…ard deviation) in the short term. For disability (0-100 scale), acupuncture (mean difference −10.52, 95% credible intervals −11.84 to −6.59…

…pacity). IV/IM SACT involving 206 vials and costing £65,452.20. Dinutuximab, at £7,600 per vial, accounted for the greatest financial loss.…

…elial growth factor (anti-VEGF) agents, such as aflibercept and ranibizumab, are widely used. Although generally safe, they carry a risk of…

…nd pancreatic pathologies, whose most prevalent complication is cholangitis, with high morbidity and mortality. Proper antibiotic prophylax…

…pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy bioma…

…cancer immunotherapy clinical trials (OAK and POPLAR, comparing atezolizumab to docetaxel in non-small cell lung cancer) as well as a separa…

…rted in 8/21 (38%) hMPV versus 21/85 (25%) RSV and 34/136 (25%) influenza A patients, (p = 0.419). Median hospital stay was shortest in hMP…

…l interaction P values for data presented were >0.05.Conclusion Dupilumab reduced moderate or severe exacerbation rates, and improved lun…

… Germany) a median of 38 hours (~1.5 days) following injury. As sepsis and IFIs typically develop a median of 3 days post-injury (medi…

…We examined hs-CRP from both the large multicentre cohort study UK Biobank and Chinese Retinal Artery Occlusion study. Cox proportional ha…

…fully affect dose–volume distributions and downstream toxicity. Head and neck cancer is particularly sensitive to subtle dosimetric differences. Sma…